Citrus flavonoid naringenin inhibits TLR2 expression in adipocytes

Journal of Nutritional Biochemistry

Volumn 24, Issue 7, 2013, Pages 1276-1284

  Yoshida, Hiroki ^a   Watanabe, Wataru ^a   Oomagari, Hiroyuki ^a   Tsuruta, Eisuke ^a   Shida, Mikiko ^a   Kurokawa, Masahiko ^a  

^a KYUSHU UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Adipocyte; Inflammation; Naringenin; Obesity; Toll like receptor

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NARINGENIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; FLAVANONE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; TLR2 PROTEIN, MOUSE;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DIFFERENTIATION; COCULTURE; CONTROLLED STUDY; DRUG EFFECT; HYPERGLYCEMIA; INFLAMMATION; INTRACELLULAR SIGNALING; LIPID DIET; MACROPHAGE; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; 3T3 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMISTRY; CITRUS; CYTOLOGY; DRUG EFFECTS; METABOLISM;

CITRUS; MUS;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; CELL DIFFERENTIATION; CITRUS; COCULTURE TECHNIQUES; FLAVANONES; MALE; MAP KINASE KINASE 4; MICE; MICE, INBRED C57BL; NF-KAPPA B; PPAR GAMMA; TOLL-LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84879305088     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2012.10.003     Document Type: Article

References (72)

1. Cawthorn W.P., Sethi J.K. TNF-alpha and adipocyte biology. FEBS Lett 2008, 582:117-131.
2. Yu R., Kim C.S., Kwon B.S., Kawada T. Mesenteric adipose tissue-derived monocyte chemoattractant protein-1 plays a crucial role in adipose tissue macrophage migration and activation in obese mice. Obesity (Silver Spring) 2006, 14:1353-1362.
3. Arner P. Insulin resistance in type 2 diabetes: role of fatty acids. Diabetes Metab Res Rev 2002, 18(Suppl 2):S5-S9.
4. Dandona P., Aljada A., Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004, 25:4-7.
5. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112:1821-1830.
6. Shoelson S.E., Lee J., Goldfine A.B. Inflammation and insulin resistance. J Clin Invest 2006, 116:1793-1801.
7. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808.
8. Akira S., Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511.
9. Akira S., Takeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001, 2:675-680.
10. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001, 1:135-145.
11. Kaisho T., Akira S. Toll-like receptor function and signaling. J Allergy Clin Immunol 2006, 117:979-987.
12. Lin Y., Lee H., Berg A.H., Lisanti M.P., Shapiro L., Scherer P.E. The lipopolysaccharide-activated toll-like receptor (TLR)-4 induces synthesis of the closely related receptor TLR-2 in adipocytes. J Biol Chem 2000, 275:24255-24263.
13. Lang C.H., Silvis C., Deshpande N., Nystrom G., Frost R.A. Endotoxin stimulates in vivo expression of inflammatory cytokines tumor necrosis factor alpha, interleukin-1beta, -6, and high-mobility-group protein-1 in skeletal muscle. Shock 2003, 19:538-546.
14. Batra A., Pietsch J., Fedke I., Glauben R., Okur B., Stroh T., et al. Leptin-dependent toll-like receptor expression and responsiveness in preadipocytes and adipocytes. Am J Pathol 2007, 170:1931-1941.
15. Creely S.J., McTernan P.G., Kusminski C.M., Fisher M., Da Silva N.F., Khanolkar M., et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab 2007, 292:E740-E747.
16. Song M.J., Kim K.H., Yoon J.M., Kim J.B. Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem Biophys Res Commun 2006, 346:739-745.
17. Hirai S., Kim Y.I., Goto T., Kang M.S., Yoshimura M., Obata A., et al. Inhibitory effect of naringenin chalcone on inflammatory changes in the interaction between adipocytes and macrophages. Life Sci 2007, 81:1272-1279.
18. Kopp A., Buechler C., Neumeier M., Weigert J., Aslanidis C., Schölmerich J., et al. Innate immunity and adipocyte function: ligand-specific activation of multiple Toll-like receptors modulates cytokine, adipokine, and chemokine secretion in adipocytes. Obesity (Silver Spring) 2009, 17:648-656.
19. Poulain-Godefroy O., Le Bacquer O., Plancq P., Lecoeur C., Pattou F., Frühbeck G., et al. Inflammatory role of Toll-like receptors in human and murine adipose tissue. Mediators Inflamm 2010, 2010:823486.
20. Fresno M., Alvarez R., Cuesta N. Toll-like receptors, inflammation, metabolism and obesity. Arch Physiol Biochem 2011, 117:151-164.
21. Lee J.Y., Zhao L., Youn H.S., Weatherill A.R., Tapping R., Feng L., et al. Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J Biol Chem 2004, 279:16971-16979.
22. Senn J.J. Toll-like receptor-2 is essential for the development of palmitate-induced insulin resistance in myotubes. J Biol Chem 2006, 281:26865-26875.
23. Shi H., Kokoeva M.V., Inouye K., Tzameli I., Yin H., Flier J.S. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006, 116:3015-3025.
24. Suganami T., Tanimoto-Koyama K., Nishida J., Itoh M., Yuan X., Mizuarai S., et al. Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol 2007, 27:84-91.
25. Poggi M., Bastelica D., Gual P., Iglesias M.A., Gremeaux T., Knauf C., et al. C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. Diabetologia 2007, 50:1267-1276.
26. Tsukumo D.M., Carvalho-Filho M.A., Carvalheira J.B., Prada P.O., Hirabara S.M., Schenka A.A., et al. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 2007, 56:1986-1998.
27. Kim F., Pham M., Luttrell I., Bannerman D.D., Tupper J., Thaler J., et al. Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ Res 2007, 100:1589-1596.
28. Davis J.E., Gabler N.K., Walker-Daniels J., Spurlock M.E. Tlr-4 deficiency selectively protects against obesity induced by diets high in saturated fat. Obesity (Silver Spring) 2008, 16:1248-1255.
29. Himes R.W., Smith C.W. Tlr2 is critical for diet-induced metabolic syndrome in a murine model. FASEB J 2010, 24:731-739.
30. Kuo L.H., Tsai P.J., Jiang M.J., Chuang Y.L., Yu L., Lai K.T., et al. Toll-like receptor 2 deficiency improves insulin sensitivity and hepatic insulin signalling in the mouse. Diabetologia 2011, 54:168-179.
31. Davis J.E., Braucher D.R., Walker-Daniels J., Spurlock M.E. Absence of Tlr2 protects against high-fat diet-induced inflammation and results in greater insulin-stimulated glucose transport in cultured adipocytes. J Nutr Biochem 2011, 22:136-141.
32. van Acker F.A., Schouten O., Haenen G.R., van der Vijgh W.J., Bast A. Flavonoids can replace alpha-tocopherol as an antioxidant. FEBS Lett 2000, 473:145-148.
33. Lin H.Y., Shen S.C., Chen Y.C. Anti-inflammatory effect of heme oxygenase 1: glycosylation and nitric oxide inhibition in macrophages. J Cell Physiol 2005, 202:579-590.
34. So F.V., Guthrie N., Chambers A.F., Moussa M., Carroll K.K. Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. Nutr Cancer 1996, 26:167-181.
35. Felgines C., Texier O., Morand C., Manach C., Scalbert A., Régerat F., et al. Bioavailability of the flavanone naringenin and its glycosides in rats. Am J Physiol Gastrointest Liver Physiol 2000 Dec, 279(6):G1148-G1154.
36. Erlund I., Meririnne E., Alfthan G., Aro A. Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. J Nutr 2001, 131(2):235-241.
37. Kanaze F.I., Bounartzi M.I., Georgarakis M., Niopas I. Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. Eur J Clin Nutr 2007, 61(4):472-477.
38. Knekt P., Kumpulainen J., Järvinen R., Rissanen H., Heliövaara M., Reunanen A., et al. Flavonoid intake and risk of chronic diseases. Am J Clin Nutr 2002, 76:560-568.
39. Yoshida H., Takamura N., Shuto T., Ogata K., Tokunaga J., Kawai K., et al. The citrus flavonoids hesperetin and naringenin block the lipolytic actions of TNF-alpha in mouse adipocytes. Biochem Biophys Res Commun 2010, 394:728-732.
40. Liu L., Shan S., Zhang K., Ning Z.Q., Lu X.P., Cheng Y.Y. Naringenin and hesperetin, two flavonoids derived from Citrus aurantium up-regulate transcription of adiponectin. Phytother Res 2008, 22:1400-1403.
41. Horiba T., Nishimura I., Nakai Y., Abe K., Sato R. Naringenin chalcone improves adipocyte functions by enhancing adiponectin production. Mol Cell Endocrinol 2010, 323:208-214.
42. Mulvihill E.E., Allister E.M., Sutherland B.G., Telford D.E., Sawyez C.G., Edwards J.Y., et al. Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance. Diabetes 2009, 58:2198-2210.
43. Kannappan S., Anuradha C.V. Naringenin enhances insulin-stimulated tyrosine phosphorylation and improves the cellular actions of insulin in a dietary model of metabolic syndrome. Eur J Nutr 2010, 49:101-109.
44. Suganami T., Nishida J., Ogawa Y. A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol 2005, 25:2062-2068.
45. Harmon A.W., Harp J.B. Differential effects of flavonoids on 3T3-L1 adipogenesis and lipolysis. Am J Physiol Cell Physiol 2001, 280(4):C807-C813.
46. Kubota N., Terauchi Y., Miki H., Tamemoto H., Yamauchi T., Komeda K., et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999, 4:597-609.
47. Rosen E.D., Spiegelman B.M. Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol 2000, 16:145-171.
48. Wu Z., Rosen E.D., Brun R., Hauser S., Adelmant G., Troy A.E., et al. Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol Cell 1999, 3:151-158.
49. Rosen E.D., Hsu C.H., Wang X., Sakai S., Freeman M.W., Gonzalez F.J., et al. C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev 2002, 16:22-26.
50. Dasu M.R., Park S., Devaraj S., Jialal I. Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice. Endocrinology 2009, 150:3457-3464.
51. Wajant H., Pfizenmaier K., Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003, 10:45-65.
52. Chao C.L., Weng C.S., Chang N.C., Lin J.S., Kao S.T., Ho F.M. Naringenin more effectively inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in macrophages than in microglia. Nutr Res 2010, 30:858-864.
53. Bodet C., La V.D., Epifano F., Grenier D. Naringenin has anti-inflammatory properties in macrophage and ex vivo human whole-blood models. J Periodontal Res 2008, 43:400-407.
54. Cristofaro P., Opal S.M. Role of Toll-like receptors in infection and immunity: clinical implications. Drugs 2006, 66:15-29.
55. Ospelt C., Gay S. TLRs and chronic inflammation. Int J Biochem Cell Biol 2010, 42:495-505.
56. Drexler S.K., Foxwell B.M. The role of toll-like receptors in chronic inflammation. Int J Biochem Cell Biol 2010, 42:506-518.
57. Oishi Y., Manabe I., Tobe K., Tsushima K., Shindo T., Fujiu K., et al. Krüppel-like transcription factor KLF5 is a key regulator of adipocyte differentiation. Cell Metab 2005, 1:27-39.
58. Mori T., Sakaue H., Iguchi H., Gomi H., Okada Y., Takashima Y., et al. Role of Krüppel-like factor 15 (KLF15) in transcriptional regulation of adipogenesis. J Biol Chem 2005, 280:12867-12875.
59. Khazen W., M'Bika J.P., Collinet M., Tramoni M., Chany C., Achour A., et al. Differentiation-dependent expression of interferon gamma and toll-like receptor 9 in 3T3-F442A adipocytes. Biochimie 2007, 89:669-675.
60. Pimentel-Nunes P, Gonçalves N, Boal-Carvalho I, Afonso L, Lopes P, Roncon-Albuquerque R Jr, Soares JB, Cardoso E, Henrique R, Moreira-Dias L, Dinis-Ribeiro M, Leite-Moreira AF. Decreased Toll-interacting protein and peroxisome proliferator-activated receptor γ are associated with increased expression of Toll-like receptors in colon carcinogenesis. J Clin Pathol doi:10.1136/jclinpath-2011-200567.
61. Ghisletti S., Huang W., Ogawa S., Pascual G., Lin M.E., Willson T.M., et al. Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. Mol Cell 2007, 25:57-70.
62. Glass C.K., Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol 2010, 10:365-376.
63. Yeop Han C., Kargi A.Y., Omer M., Chan C.K., Wabitsch M., O'Brien K.D., et al. Differential effect of saturated and unsaturated free fatty acids on the generation of monocyte adhesion and chemotactic factors by adipocytes: dissociation of adipocyte hypertrophy from inflammation. Diabetes 2010, 59(2):386-396.
64. Choi J.H., Banks A.S., Estall J.L., Kajimura S., Boström P., Laznik D., et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature 2010, 466(7305):451-456.
65. Choi J.H., Banks A.S., Kamenecka T.M., Busby S.A., Chalmers M.J., Kumar N., et al. Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature 2011, 477(7365):477-481.
66. Coll T., Palomer X., Blanco-Vaca F., Escolà-Gil J.C., Sánchez R.M., Laguna J.C., et al. Cyclooxygenase 2 inhibition exacerbates palmitate-induced inflammation and insulin resistance in skeletal muscle cells. Endocrinology 2010, 151(2):537-548.
67. Kintscher U., Hartge M., Hess K., Foryst-Ludwig A., Clemenz M., Wabitsch M., et al. T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol 2008, 28(7):1304-1310.
68. Fang F., Tang Y., Gao Z., Xu Q. A novel regulatory mechanism of naringenin through inhibition of T lymphocyte function in contact hypersensitivity suppression. Biochem Biophys Res Commun 2010, 397(2):163-169.
69. Williams R.J., Spencer J.P., Rice-Evans C. Flavonoids: antioxidants or signalling molecules?. Free Radic Biol Med 2004, 36:838-849.
70. Díaz-Delfín J., Morales M., Caelles C. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway. Diabetes 2007, 56:1865-1871.
71. Chen D., Daniel K.G., Chen M.S., Kuhn D.J., Landis-Piwowar K.R., Dou Q.P. Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochem Pharmacol 2005, 69:1421-1432.
72. Goldwasser J., Cohen P.Y., Yang E., Balaguer P., Yarmush M.L., Nahmias Y. Transcriptional regulation of human and rat hepatic lipid metabolism by the grapefruit flavonoid naringenin: role of PPARalpha. PPARgamma and LXRalpha. PLoS One. 2010, 5(8):e12399.